Analyst Upgrades: Tesla, Lion Biotech, Skyworks

Analysts upwardly revised their ratings on Tesla Motors Inc (TSLA), Lion Biotechnologies Inc (LBIO), and Skyworks Solutions Inc (SWKS)

by Alex Eppstein

Published on Apr 2, 2015 at 9:14 AM
Updated on Jun 29, 2020 at 11:42 AM

Analysts are weighing in today on automaker Tesla Motors Inc (NASDAQ:TSLA), adoptive cell therapy expert Lion Biotechnologies Inc (NASDAQ:LBIO), and semiconductor concern Skyworks Solutions Inc (NASDAQ:SWKS). Here's a quick roundup of today's bullish brokerage notes on TSLA, LBIO, and SWKS.

  • One Credit Suisse analyst waxed optimistic on TSLA earlier, saying he expects strong demand in Europe -- and the note has sent the shares 1.8% higher ahead of the bell. This bullish price action represents a change of pace for Tesla Motors Inc, which has tumbled nearly 16% year-to-date to trade at $187.59. Not surprisingly, short interest has been on the upswing, rising 6.7% during the latest reporting period. Currently, more than one-quarter of TSLA's float is sold short, which represents a week's worth of trading, at typical daily volumes. Similarly skeptical are options traders, who have been buying to open puts over calls at a faster-than-usual clip in recent weeks.

  • LBIO is among a number of drugmakers catching our attention this morning, after receiving a pair of bullish notes overnight. Specifically, FBR initiated coverage on the stock with an "outperform" rating and $20 price target, while Jefferies boosted its target to $18 from $12 and underscored its "buy" opinion. Such optimism is warranted, given Lion Biotechnologies Inc's technical track record, up 59.5% year-to-date to trade at $12.55. What's more, the shares are sitting nearly 7% higher ahead of the open. Amid the equity's long-term rally, the brokerage bunch has reached a bullish consensus, with 100% of covering analysts handing out "strong buy" recommendations. If that's not enough, LBIO's average 12-month price target of $16.67 sits in territory not charted since October 2013.

  • Brean Capital upped its price target on SWKS to $110 from $92, and also re-affirmed its "buy" rating. This positivity isn't unusual in the least, as 12 analysts have given the shares a "strong buy" endorsement, compared to two "holds" and not a single "sell." However, Skyworks Solutions Inc's consensus 12-month price target of $98.41 rests just 1.6% from Wednesday's close at $96.84. Based on the stock's technicals, it seems additional price-target hikes may be in order. The shares have surged 158% year-over-year, and have outperformed the broader S&P 500 Index (SPX) by nearly 35 percentage points over the last three months. In electronic trading, SWKS is up another 1.1%.

A Schaeffer's 39th Anniversary Exclusive!

8 Top Stock Picks for 2020

Access your FREE insider report before it's too late!


  
 
 

Partnercenter